Sinopharm Group Co. Ltd - Asset Resilience Ratio
Sinopharm Group Co. Ltd (X2S) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Sinopharm Group Co. Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Sinopharm Group Co. Ltd's Asset Resilience Ratio has changed over time. See Sinopharm Group Co. Ltd (X2S) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Sinopharm Group Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Sinopharm Group Co. Ltd market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €127.00K | 0.0% |
| Total Liquid Assets | €127.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Sinopharm Group Co. Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sinopharm Group Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Sinopharm Group Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sigma Healthcare Ltd
AU:SIG |
Medical Distribution | 0.03% |
|
Ebos Group Ltd
AU:EBO |
Medical Distribution | 0.00% |
|
Paragon Care Ltd
AU:PGC |
Medical Distribution | 0.00% |
|
Mayne Pharma Group Ltd
AU:MYX |
Medical Distribution | 4.00% |
|
Cyclopharm Ltd
AU:CYC |
Medical Distribution | 1.98% |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3 |
Medical Distribution | 4.48% |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607 |
Medical Distribution | 4.44% |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SHG:600332 |
Medical Distribution | 5.56% |
Annual Asset Resilience Ratio for Sinopharm Group Co. Ltd (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Sinopharm Group Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | €158.00K ≈ $184.72K |
€392.83 Billion ≈ $459.26 Billion |
0.00pp |
| 2023-12-31 | 0.00% | €547.00K ≈ $639.50K |
€383.39 Billion ≈ $448.23 Billion |
+0.00pp |
| 2022-12-31 | 0.00% | €498.00K ≈ $582.21K |
€364.78 Billion ≈ $426.46 Billion |
0.00pp |
| 2021-12-31 | 0.00% | €11.75 Million ≈ $13.74 Million |
€335.41 Billion ≈ $392.13 Billion |
-0.01pp |
| 2020-12-31 | 0.01% | €39.14 Million ≈ $45.76 Million |
€311.24 Billion ≈ $363.87 Billion |
+0.01pp |
| 2019-12-31 | 0.00% | €156.00K ≈ $182.38K |
€269.89 Billion ≈ $315.53 Billion |
-0.02pp |
| 2018-12-31 | 0.02% | €41.20 Million ≈ $48.17 Million |
€235.77 Billion ≈ $275.64 Billion |
-0.09pp |
| 2017-12-31 | 0.10% | €175.61 Million ≈ $205.31 Million |
€169.54 Billion ≈ $198.21 Billion |
+0.10pp |
| 2016-12-31 | 0.00% | €5.47 Million ≈ $6.39 Million |
€157.71 Billion ≈ $184.38 Billion |
-0.88pp |
| 2015-12-31 | 0.88% | €1.23 Billion ≈ $1.44 Billion |
€139.43 Billion ≈ $163.01 Billion |
-0.04pp |
| 2014-12-31 | 0.93% | €1.19 Billion ≈ $1.39 Billion |
€128.66 Billion ≈ $150.41 Billion |
+0.10pp |
| 2013-12-31 | 0.83% | €874.07 Million ≈ $1.02 Billion |
€105.45 Billion ≈ $123.29 Billion |
-- |
About Sinopharm Group Co. Ltd
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical … Read more